Literature DB >> 8064662

Monoclonal gammopathy in a dog with visceral leishmaniasis.

A Font1, J M Closa, J Mascort.   

Abstract

One dog with visceral leishmaniasis associated with monoclonal gammopathy is described. Most dogs with visceral leishmaniasis present with hyperproteinemia due to a polyclonal gammopathy, but the possibility of monoclonal gammopathy must be considered. Because dogs accompany their owners when they travel, the diagnosis of leishmaniasis should be considered if an animal with monoclonal gammopathy has visited an area where the disease is endemic. The observation of Leishmania in the macrophages of a bone marrow, lymph node smear, or skin biopsy specimen is diagnostic.

Entities:  

Mesh:

Year:  1994        PMID: 8064662     DOI: 10.1111/j.1939-1676.1994.tb03223.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  4 in total

1.  Monoclonal gammopathy associated with multiple myeloma and visceral leishmaniasis in the dog: a comparison of two cases.

Authors:  M T Antognoni; F Birettoni; A Miglio; P Lalli; F Porciello; V Mangili Pecci
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

2.  Leishmanial polyarthritis in a dog.

Authors:  Sandra E McConkey; Alfonso López; Darcy Shaw; Jill Calder
Journal:  Can Vet J       Date:  2002-08       Impact factor: 1.008

3.  Results of histopathology, immunohistochemistry, and molecular clonality testing of small intestinal biopsy specimens from clinically healthy client-owned cats.

Authors:  Sina Marsilio; Mark R Ackermann; Jonathan A Lidbury; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2019-02-28       Impact factor: 3.333

4.  Clonality testing in the lymph nodes from dogs with lymphadenomegaly due to Leishmania infantum infection.

Authors:  Antonio Melendez-Lazo; Anne-Katherine Jasensky; Ico Thais Jolly-Frahija; Alexandra Kehl; Elisabeth Müller; Ignacio Mesa-Sánchez
Journal:  PLoS One       Date:  2019-12-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.